Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Stephens Consulting LLC

Stephens Consulting LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 325.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 340 shares of the biopharmaceutical company’s stock after buying an additional 260 shares during the period. Stephens Consulting LLC’s holdings in Gilead Sciences were worth $31,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Bellevue Group AG boosted its holdings in shares of Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after purchasing an additional 7,093 shares during the last quarter. Quantinno Capital Management LP boosted its stake in Gilead Sciences by 149.5% in the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after buying an additional 48,910 shares during the last quarter. IRON Financial LLC purchased a new stake in Gilead Sciences in the 3rd quarter valued at about $830,000. Capital Investment Advisors LLC increased its stake in shares of Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after acquiring an additional 9,791 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of Gilead Sciences by 12.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company’s stock worth $27,081,000 after acquiring an additional 36,895 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

GILD has been the topic of a number of recent analyst reports. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Finally, BMO Capital Markets raised their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $98.39.

Gilead Sciences Stock Up 1.2 %

Shares of Gilead Sciences stock opened at $98.38 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The business has a 50-day moving average price of $92.42 and a 200 day moving average price of $85.96. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $99.45. The firm has a market cap of $122.61 billion, a P/E ratio of 1,093.11, a P/E/G ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the prior year, the company posted $2.29 EPS. The business’s revenue was up 7.0% compared to the same quarter last year. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 598,414 shares of company stock valued at $55,953,200. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.